Business Wire

MFA Launches Network Identifier Program for Enterprises to Deploy Their Own Private Network

16.11.2021 17:00:00 EET | Business Wire | Press release

Share

MFA, an international organization championing the global industry adoption of private networks based upon 3GPP technologies, today announced its Network Identifier Program for enterprises. Enterprises now have access to the MFA’s unique global PLMN ID that they can use when deploying their own private network to ensure that only authorized devices connect to their network. The program reduces complexity and streamlines the network development process for enterprises by eliminating the need for them to separately apply for their own PLMN ID.

“Our mission is to make it as easy as possible for enterprises to quickly deploy their own private network and realize the benefits of greater control over their network, enhanced on-premise data security, and predictable performance,” said Mazen Chmaytelli, president, MFA. “MFA was awarded a unique global PLMN ID by the ITU, and we are creating this new program to ensure all industry verticals have ready access to a PLMN ID that will support their digitalization journey.”

Enterprises and industry verticals including maritime, manufacturing, warehouses, utilities, and venues can select a Private Network ID package or a Neutral Host Network (NHN) ID package that will provide them with all the items they need to deploy a neutral host or private network. For large deployments, enterprises will be able to add-on IDs to meet their requirements for coverage and capacity.

“With access to the global PLMN ID from MFA, network suppliers or operators will have the necessary identifiers to create unique and distinguishable private networks, streamlining the deployment process for their enterprise customers – anywhere in the world they are located,” said Asimakis Kokkos, MFA Technical Specification Group Chair and Head of Technology Ecosystems, Nokia Enterprise Solutions.

New Private Network Subscriber category created to jumpstart deployment
MFA has also created a new Private Network Subscriber category that will grant enterprises one complimentary Private Network ID package that they can use immediately to deploy their own 5G private network in locally licensed spectrum or MulteFire®/4G private network in unlicensed spectrum today.

“For a one-time fee, Private Network Subscribers gain access to a Private Network ID package that is evergreen and does not need to be renewed,” added Chmaytelli. “Our members also will receive complimentary packages that will meet their deployment requirements. The MFA wants to help seed as many private networks as possible, and we’re excited to bring this important program to the entire industry.”

To further enable private network deployments, MFA, a 3GPP Market Representation Partner (MRP), previously announced that it is also developing Uni5G™ Technology Blueprints. These blueprints will provide enterprises with practical guidance on implementing the key features from the 3GPP 5G standards that are relevant to their specific deployment. The first blueprints will be finalized in December 2021.

The Network Identifier program is administered by the MFA Certificate Authority and is available today to MFA members and non-members. For companies interested in joining the program, visit www.mfa-tech.org.

Resources:

About MFA
MFA is an international organization that is championing the global industry adoption of private networks using MFA-defined MulteFire specifications for LTE and Uni5G Technology Blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MFA
Lori Mesecke, +1-503-459-9150
press@mfa-tech.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye